Raptiva - Efalizumab - Dosage - Side Effects - Interactions - Warnings
Update: On April 8, 2009, Genentech, Inc. announced a phased voluntary withdrawal of the psoriasis drug Raptiva (efalizumab) from the U.S. market based on the association of Raptiva with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system.
- A - Z: Arthritis Drugs
- A - Z: Biologics / Blockers
- A - Z: Drug Costs
- Needlephobia Overview
- Psoriatic Arthritis
The Facts of Raptiva (Efalizumab)
Raptiva (Efalizumab) is a subcutaneous injection used to treat adult patients with moderate to severe plaque psoriasis whose psoriasis is appropriate for treatment with whole body (systemic therapy) or phototherapy.
Drugs A-Z - Raptiva / Efalizumab Injection
Patient education for Raptiva / efalizumab injection.
03/28/2004 Raptiva History: Raptiva Fails Psoriatic Arthritis Trial
03/28/2004, Study results show Raptiva (efalizumab) did not show statistical significance in improving symptoms of psoriatic arthritis by at least 20 percent.
05/13/2003 Raptiva History: Raptiva Rheumatoid Arthritis Trial Halted
05/13/2003, Genentech and Xoma stop development of the drug Raptiva (efalizumab) for rheumatoid arthritis.
06/20/2005 Raptiva History: Label To Include Hemolytic Anemia Warning
06/20/2005, FDA adds new warnings on the Genentech psoriasis drug Raptiva (efalizumab) following reports of four cases of hemolytic anemia diagnosed four to six months after patients started on the monoclonal antibody, from FDA (pdf).
